Literature DB >> 16432163

The sulindac derivatives OSI-461, OSIP486823, and OSIP487703 arrest colon cancer cells in mitosis by causing microtubule depolymerization.

Danhua Xiao1, Atsuko Deguchi, Gregg G Gundersen, Bert Oehlen, Lee Arnold, I Bernard Weinstein.   

Abstract

Exisulind (sulindac sulfone) and three highly potent derivatives, OSI-461 (CP461), OSIP486823 (CP248), and OSIP487703, inhibit growth and induce apoptosis in SW480 human colon cancer cells, with IC(50)s of 200, 2, 0.1, and 0.003 micromol/L, respectively. The latter three compounds, but not exisulind, induce marked M-phase cell cycle arrest in these cells. This effect seems to be independent of the known ability of these compounds to cause activation of protein kinase G. When tested at twice their IC(50) concentration for growth inhibition, OSI-461, OSIP486823, and OSIP487703 cause depolymerization of microtubules in interphase cells, inhibit spindle formation in mitotic cells, and induce multinucleated cells. In vitro tubulin polymerization assays indicate that all three compounds interact with tubulin directly to cause microtubule depolymerization and/or inhibit de novo tubulin polymerization. These results suggest that the dual effects of OSI-461, OSIP486823, and OSIP487703 on impairment of microtubule functions and protein kinase G activation may explain the potent antiproliferative and apoptotic effects of these compounds in cancer cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16432163     DOI: 10.1158/1535-7163.MCT-05-0260

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  5 in total

1.  A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state.

Authors:  C L O'Bryant; C H Lieu; S Leong; R Boinpally; M Basche; L Gore; K Leonardi; M K Schultz; S Hariharan; L Chow; S Diab; A Gibbs; S G Eckhardt
Journal:  Cancer Chemother Pharmacol       Date:  2008-05-29       Impact factor: 3.333

2.  Synthesis and biological activity of NOSH-naproxen (AVT-219) and NOSH-sulindac (AVT-18A) as potent anti-inflammatory agents with chemotherapeutic potential.

Authors:  Ravinder Kodela; Mitali Chattopadhyay; Khosrow Kashfi
Journal:  Medchemcomm       Date:  2013       Impact factor: 3.597

3.  NOSH-sulindac (AVT-18A) is a novel nitric oxide- and hydrogen sulfide-releasing hybrid that is gastrointestinal safe and has potent anti-inflammatory, analgesic, antipyretic, anti-platelet, and anti-cancer properties.

Authors:  Khosrow Kashfi; Mitali Chattopadhyay; Ravinder Kodela
Journal:  Redox Biol       Date:  2015-08-14       Impact factor: 11.799

4.  Screening and Development of New Inhibitors of FtsZ from M. Tuberculosis.

Authors:  Bini Mathew; Judith Varady Hobrath; Larry Ross; Michele C Connelly; Hava Lofton; Malini Rajagopalan; R Kiplin Guy; Robert C Reynolds
Journal:  PLoS One       Date:  2016-10-21       Impact factor: 3.240

Review 5.  Colchicine-Binding Site Inhibitors from Chemistry to Clinic: A Review.

Authors:  Eavan C McLoughlin; Niamh M O'Boyle
Journal:  Pharmaceuticals (Basel)       Date:  2020-01-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.